HORMESIS AND GINKGO BILOBA (GB): Numerous Biological Effects of GB are Mediated via Hormesis.
HORMESIS AND GINKGO BILOBA (GB): Numerous Biological Effects of GB are Mediated via Hormesis. Ageing Res Rev. 2020 Jan 10;:101019 Authors: Calabrese EJ, Calabrese V, Tsatsakis A, Giordano JJ Abstract Ginkgo biloba (GB) extracts have been shown to commonly induce biphasic dose responses in a range of cell types and endpoints (e.g., cochlea neural stem cells, cell viability, cell proliferation). The magnitude and width of the low dose stimulation of these biphasic dose responses are similar to those reported for hormetic dose responses. These hormetic dose responses occur within direct stimulatory responses as well as in preconditioning experimental protocols, displaying acquired resistance within an adaptive homeodynamic and temporal framework and repeated measurement protocols. The demonstrated GB dose responses further reflect the general occurrence of hormetic dose responses that consistently appear to be independent of the biological model, endpoint, inducing agent, and/or mechanism. These findings have important implications for consideration(s) of study designs involving dose selection, dose spacing, sample size, and statistical power. This illustrates and strengthens the need to characterize the low dose stimulatory response range and optimal dose in order to explore potential public health and clinical applications of plant-derived agents, such as GB. PMID: 31931153 [PubMed - as supplied by publisher]
Publication date: Available online 28 May 2020Source: MethodsAuthor(s): Prakhar Mishra, Richard I. Cohen, Nanxia Zhao, Prabhas V. Moghe
Conclusion: The full regeneration of solar elastosis was obtained by injection of in vitro expanded autologous adipose mesenchymal stem cells, which are appropriate, competent, and sufficient to elicit the full structural regeneration of the sun-aged skin. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
No abstract available
No abstract available
Data offers valuable resource for developing stem cell-based therapies for hearing loss
Publication date: Available online 27 May 2020Source: Stem Cell ResearchAuthor(s): Yunpan Li, David P. Ibañez, Wenxia Fan, Ping Zhao, Shuhan Chen, Mazid Md. Abdul, Zhiwei Luo, Zhenhua Liu, Jifeng Guo, Giacomo Volpe, Shahzina Kanwal, Dongye Wang, Beisha Tang, Wenjuan Li
Publication date: Available online 26 May 2020Source: Materials Science and Engineering: CAuthor(s): Gyeongju Kim, Yuna Jung, Kanghee Cho, Hyun Jong Lee, Won-Gun Koh
On May 14, 2020, Pluristem Therapeutics Inc. published follow-up data on patients treated under their compassionate use program. These patients were all being treated for with Acute Respiratory Distress Syndrome (ARDS) associated with the SARS-CoV-2 virus, and in intensive care units requiring mechanical ventilation. As of the publication date, 18 patients have been treated with PLX cells, allogeneic mesenchymal-like cells derived from human placentas after the delivery of full-term healthy babies. The patients treated include one patient in the United States. This patient received the treatment as part of the FDA Single P...
A new double-contrast MRI technique in development could help the modality...Read more on AuntMinnie.comRelated Reading: COVID-19 neuro findings marked by mental status, stroke fMRI-based machine learning helps predict coma outcomes ISMRM annual meeting goes virtual MRI illuminates neurologic manifestations of COVID-19 MRI could help predict efficacy of stem cell therapy
Basel, 28 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced European Medicines Agency (EMA) approval of a new, shorter two-hour OCREVUS ® (ocrelizumab) infusion time, dosed twice yearly, for relapsing or primary progressive multiple sclerosis (MS). The approval is based on a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP).“The approval of a shorter, two-hour infusion time for OCREVUS in Europe, dosed twice yearly, will further improve the treatment experience for patients while als...